Holen Sie sich die Stockscreener-App
6.00
14.94%
0.78
Handel nachbörslich:
6.00
Schlusskurs vom Vortag:
$5.22
Offen:
$4.9
24-Stunden-Volumen:
1.13M
Relative Volume:
3.87
Marktkapitalisierung:
$310.13M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.90M
KGV:
-11.32
EPS:
-0.53
Netto-Cashflow:
$-19.80M
1W Leistung:
+27.12%
1M Leistung:
+65.29%
6M Leistung:
-4.00%
1J Leistung:
+67.60%
1-Tages-Spanne:
$4.90
$6.40
1-Wochen-Bereich:
$4.39
$6.40
52-Wochen-Spanne:
$3.19
$6.8184
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
Firmenname
Diamedica Therapeutics Inc
Sektor
Branche
Telefon
(763) 496-5454
Adresse
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Vergleichen Sie DMAC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
6.00 | 268.78M | 0 | -19.90M | -19.80M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-24 | Fortgesetzt | Craig Hallum | Buy |
| 2023-06-22 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-04-09 | Eingeleitet | Oppenheimer | Outperform |
| 2021-02-17 | Eingeleitet | ROTH Capital | Buy |
| 2020-10-30 | Eingeleitet | Guggenheim | Buy |
| 2020-07-08 | Eingeleitet | Maxim Group | Buy |
| 2019-04-30 | Eingeleitet | Dougherty & Company | Buy |
| 2019-03-05 | Eingeleitet | Lake Street | Buy |
Alle ansehen
Diamedica Therapeutics Inc Aktie (DMAC) Neueste Nachrichten
DiaMedica: Interim Results Brings Study Expansions For DM199 In Preeclampsia (NASDAQ:DMAC) - Seeking Alpha
Diamedica Therapeutics shares rise 14.94% intraday after Celcuity's positive Phase 3 trial results. - AInvest
DiaMedica Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Diamedica Therapeutics shares rise 1.92% intraday after Q2 2025 earnings call. - AInvest
Earnings call transcript: DiaMedica Therapeutics Q2 2025 shows promising trials By Investing.com - Investing.com South Africa
Earnings call transcript: DiaMedica Therapeutics Q2 2025 shows promising trials - Investing.com India
Will DiaMedica Therapeutics Inc. see short term momentumCEO Change & Entry Point Strategy Guides - Newser
What to expect from DiaMedica Therapeutics Inc. in the next 30 daysWeekly Market Summary & Expert Approved Momentum Ideas - Newser
Pattern recognition hints at DiaMedica Therapeutics Inc. upside2025 Trade Ideas & Fast Gain Stock Tips - Newser
Technical signs of recovery in DiaMedica Therapeutics Inc.Weekly Investment Report & Free Reliable Trade Execution Plans - Newser
DiaMedica Posts Narrower Loss in Q2 - AOL.com
Technical analysis overview for DiaMedica Therapeutics Inc. stockJuly 2025 Update & Accurate Technical Buy Alerts - Newser
What indicators show strength in DiaMedica Therapeutics Inc. [Short Setup]Weekly Top Gainers Trade List - Newser
DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights - BioSpace
Full technical analysis of DiaMedica Therapeutics Inc. stockAI Intraday Market Movement Prediction Tool - Newser
DiaMedica Therapeutics Enters Sales Agreement with TD Securities - TipRanks
Is this a good reentry point in DiaMedica Therapeutics Inc.Fast Entry Strategy with Price Prediction - Newser
DiaMedica Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Can DiaMedica Therapeutics Inc. sustain its profitabilityReal-Time Trade Breakout Scanner - thegnnews.com
Screener Results Flag DiaMedica Therapeutics Inc. as OversoldROI Driven Equity Selection With Safety Emphasized - 선데이타임즈
What data driven models say about DiaMedica Therapeutics Inc.’s futureRapid Trade Forecast Based on Indicators - Newser
Momentum divergence signals in DiaMedica Therapeutics Inc. chartAutomated AI Forecast with Trading Alerts - Newser
Fair Value Estimate for DiaMedica Therapeutics: $5.11; Share Price Matches Fair Value; Analyst Price Target Exceeds Fair Value. - AInvest
Volume spikes in DiaMedica Therapeutics Inc. stock – what they meanShort-Term AI-Based Stock Price Forecast - Newser
What’s the recovery path for long term holders of DiaMedica Therapeutics Inc. - Newser
What makes DiaMedica Therapeutics Inc. stock price move sharplyFree AI Based High Gain Watchlist Scanner - Newser
Press Release: DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025 - 富途牛牛
Intrinsic Value of DiaMedica Therapeutics Inc. Stock: Is It Undervalued or OvervaluedBuy Zone Strategy with Pattern Recognition - Newser
Can momentum traders help lift DiaMedica Therapeutics Inc.Free Low Risk Buy Zone Opportunity Watch - Newser
DiaMedica Therapeutics Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
What indicators show strength in DiaMedica Therapeutics Inc.Conservative Equity Setup with Signal Analysis - Newser
DiaMedica Therapeutics appoints Julie Krop as Chief Medical Officer - MSN
DiaMedica Appoints New Chief Medical Officer - The Globe and Mail
Intraday pattern recognizer results for DiaMedica Therapeutics Inc.Swing Entry Insight With Forecast Accuracy - Newser
Diamedica Therapeutics shares rise 3.12% intraday after appointing Julie Krop, MD, as Chief Medical Officer. - AInvest
DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer. - AInvest
DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer - Business Wire
DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025 - Lelezard
Diamedica Therapeutics To Report Second Quarter 2025 Financial Results And Provide A Business Update August 13, 2025 - TradingView
Can trapped investors hope for a rebound in DiaMedica Therapeutics Inc.Price Action Trading with Volume Confirmation - Newser
Finanzdaten der Diamedica Therapeutics Inc-Aktie (DMAC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):